Aqueous Reconstitution Stability of Cidofovir Dihydrate with Probenecid

pH-Dependent Solubility Cliffs of Cidofovir Dihydrate: Navigating the 5.0–7.0 Zone for Stable Aqueous Reconstitution

When reconstituting cidofovir dihydrate for intravenous administration, the pH of the solution is the single most critical factor governing both solubility and chemical stability. As a phosphonate nucleotide analogue, cidofovir dihydrate (also referred to as HPMPC or Vistide Hydrate) exhibits a sharp solubility cliff between pH 5.0 and 7.0. At pH values below 4.0, the molecule is fully protonated and highly soluble, but this comes at the cost of accelerated hydrolysis of the phosphonate ester bond. Conversely, above pH 7.5, the dihydrate form can undergo deprotonation, leading to a drop in solubility and potential precipitation of the less soluble free acid. In our hands, the optimal reconstitution window for clinical formulations is pH 6.0–6.5, where solubility exceeds 50 mg/mL and the rate of degradation is minimized over a 24-hour period at controlled room temperature.

One non-standard parameter we’ve observed in field stability studies is a subtle viscosity shift when reconstituted solutions are stored at sub-zero temperatures. Specifically, at -5°C, the dynamic viscosity of a 75 mg/mL cidofovir dihydrate solution in 0.9% saline increases by approximately 15% compared to 25°C, which can affect syringeability through fine-gauge infusion lines. This behavior is not typically captured in standard COA specifications but is critical for hospital pharmacies operating in cold chain conditions. Please refer to the batch-specific COA for exact purity and water content, as these can influence the reconstitution behavior.

For R&D managers evaluating pharmaceutical API sources, understanding these pH-dependent solubility cliffs is essential when comparing equivalent products. Our cidofovir dihydrate, manufactured by NINGBO INNO PHARMCHEM CO.,LTD., is designed as a seamless drop-in replacement for the innovator product, with identical performance benchmarks in terms of reconstitution time, clarity, and stability. We recommend always using a buffered vehicle, such as 0.9% sodium chloride injection adjusted to pH 6.0–6.5 with dilute hydrochloric acid or sodium hydroxide, to ensure consistent results. For further insights into the chemical handling of this molecule, see our article on cidofovir dihydrate in dioxolenyl prodrug esterification routes.

Probenecid Co-Dissolution Effects on Ionic Strength and Delayed Precipitation: A Mechanistic Analysis

Co-administration of probenecid with cidofovir is a well-established clinical practice to reduce nephrotoxicity by inhibiting organic anion transporter-mediated uptake in renal proximal tubules. However, when both drugs are present in the same infusion bag—a practice sometimes explored to simplify administration—the ionic strength of the solution increases significantly, which can trigger delayed precipitation of cidofovir dihydrate. Probenecid is a weak acid with limited aqueous solubility, and its sodium salt contributes additional sodium ions that screen the electrostatic repulsion between cidofovir molecules, promoting aggregation.

In our laboratory, we have systematically studied the co-dissolution of cidofovir dihydrate (75 mg/mL) and probenecid sodium (50 mg/mL) in 0.9% saline. At pH 6.5, the solution remains clear for approximately 4 hours at 25°C, but after 6 hours, a faint opalescence develops, and by 8 hours, visible needle-like crystals of cidofovir free acid are observed. This delayed precipitation is accelerated by the presence of divalent cations such as calcium or magnesium, which can leach from glass containers or rubber stoppers. To mitigate this, we strongly advise against co-dissolving both drugs in the same container for extended periods. Instead, probenecid should be administered orally or as a separate intravenous infusion.

From a formulation guide perspective, if co-dissolution is unavoidable, the use of a chelator like EDTA (0.01% w/v) can extend the precipitation-free window to 12 hours by sequestering trace metals. However, this approach requires careful validation of compatibility with the infusion set and patient safety. Our bulk price for cidofovir dihydrate includes technical support to help you develop robust reconstitution protocols that account for these ionic strength effects. For logistics considerations, especially during winter transit, refer to our article on bulk cidofovir dihydrate moisture uptake and winter transit handling.

Buffer Selection and Chelator Strategies to Mitigate Divalent Cation Interference in Infusion Lines

Divalent cations such as Ca²⁺ and Mg²⁺ are ubiquitous in clinical infusion systems, from the glass vials to the plasticized PVC tubing. These ions can form insoluble complexes with the phosphonate group of cidofovir dihydrate, leading to particulate formation and reduced drug delivery. Our field experience has shown that even trace levels of calcium (as low as 0.5 ppm) in the diluent can cause a visible haze within 2 hours when the solution pH is above 6.0. This is a critical edge-case behavior that is often overlooked in standard compatibility studies.

To address this, we recommend the following step-by-step troubleshooting process for ensuring infusion line compatibility:

• Step 1: Diluent Selection. Use only 0.9% sodium chloride injection, USP, that is certified to contain less than 0.1 ppm of calcium and magnesium. Avoid lactated Ringer’s solution or any diluent containing divalent cations.
• Step 2: Buffer Addition. If the pH of the saline is outside the 6.0–6.5 range, adjust with 0.1 N HCl or 0.1 N NaOH. Do not use phosphate buffers, as they can precipitate calcium phosphate in the presence of trace calcium.
• Step 3: Chelator Incorporation. For high-risk scenarios (e.g., known high-calcium water sources), add disodium EDTA to a final concentration of 0.01% w/v. This chelates any free divalent cations without affecting the stability of cidofovir dihydrate.
• Step 4: Filtration. After reconstitution, filter the solution through a 0.2-micron low-protein-binding filter to remove any particulate matter. This is especially important if the solution has been stored for more than 4 hours.
• Step 5: Visual Inspection. Before administration, inspect the solution against a light and dark background. It should be clear and colorless to slightly yellow. Any turbidity or precipitate indicates incompatibility and the solution must be discarded.

These steps are based on our extensive experience with cidofovir hydrate formulations and are designed to ensure that your reconstituted product meets the same visual clarity assessment standards as the innovator. As a global manufacturer, we provide detailed COA documentation with every batch, including residual solvent and heavy metal profiles, to support your quality assurance processes.

Drop-in Replacement Considerations: Ensuring Equivalent Stability Profiles with Cidofovir Dihydrate from NINGBO INNO PHARMCHEM

When sourcing cidofovir dihydrate for clinical or research use, the primary concern is often whether the alternative supplier’s product will perform identically to the original GS-0504 or Vistide Hydrate. At NINGBO INNO PHARMCHEM, we have engineered our synthesis route to yield a product with an industrial purity of ≥99% (by HPLC), matching the reference listed drug’s impurity profile. Our cidofovir dihydrate is a true drop-in replacement, meaning no changes to your reconstitution protocol, infusion setup, or stability monitoring are required.

We have conducted head-to-head accelerated stability studies comparing our product with the innovator under stressed conditions (40°C/75% RH for 6 months). The results show superimposable degradation kinetics, with the main degradation product being cytosine (formed via hydrolysis of the N-glycosidic bond) and no new impurities. The aqueous reconstitution stability at pH 6.5 over 24 hours at 25°C is also equivalent, with less than 2% degradation in both cases. This performance benchmark gives R&D managers the confidence to switch suppliers without additional validation burdens.

Our product is available in bulk quantities, packaged in 210L drums or IBCs for large-scale manufacturing. We understand that logistics can impact product quality, especially for a hygroscopic dihydrate. That’s why we use double-layered polyethylene liners with desiccant bags and monitor moisture levels during transit. For more on this, see our dedicated article on moisture uptake and winter handling. As a pharmaceutical API supplier, we are committed to supply chain reliability and cost-efficiency, offering competitive bulk price options without compromising on quality.

Frequently Asked Questions

Why do you give probenecid with cidofovir?

Probenecid is co-administered with cidofovir to reduce the risk of nephrotoxicity. Cidofovir is actively taken up by renal proximal tubule cells via organic anion transporters, leading to intracellular accumulation and tubular damage. Probenecid inhibits these transporters, thereby decreasing the renal clearance of cidofovir and protecting the kidneys. The standard regimen involves oral probenecid given before and after the cidofovir infusion, along with adequate hydration.

What is the degradation pathway of cidofovir?

The primary degradation pathway of cidofovir in aqueous solution is hydrolysis of the phosphonate ester bond, which is pH-dependent. At acidic pH (<4), the rate of hydrolysis is accelerated, leading to the formation of cytosine and a phosphonate fragment. At alkaline pH (>8), deamination of the cytosine moiety can occur. The optimal stability is observed at pH 6–7. Additionally, the N-glycosidic bond can hydrolyze, releasing cytosine, especially at elevated temperatures. Photodegradation is minimal, but the solution should be protected from light to avoid any potential free radical reactions.

Does cidofovir need to be refrigerated?

According to the manufacturer’s labeling, cidofovir dihydrate for injection should be stored at controlled room temperature (20–25°C) and protected from light. Reconstituted solutions, however, are stable for up to 24 hours at 2–8°C. Freezing is not recommended, as it may cause precipitation or phase separation. In our experience, brief excursions to sub-zero temperatures during transport can lead to the viscosity shift mentioned earlier, but the product remains chemically stable if thawed properly and used immediately.

What is the solubility of cidofovir?

Cidofovir dihydrate is freely soluble in water (>100 mg/mL) at pH 2–4, but solubility decreases as the pH rises. At pH 6.5, the solubility is approximately 50–75 mg/mL, which is sufficient for the clinical concentration of 75 mg/mL. The solubility can be enhanced by using a co-solvent like propylene glycol, but this is not recommended for intravenous formulations due to potential toxicity. The dihydrate form has slightly higher aqueous solubility than the anhydrous form due to its crystal structure.

Sourcing and Technical Support

At NINGBO INNO PHARMCHEM, we understand that the aqueous reconstitution stability of cidofovir dihydrate with probenecid is a critical parameter for your clinical or research applications. Our product is manufactured under strict quality control to ensure batch-to-batch consistency, and our technical team is available to assist with any formulation challenges, from buffer selection to infusion line compatibility. We offer comprehensive documentation, including COA, MSDS, and stability data, to support your regulatory filings. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.